Immunobiology of solid organ transplantation

International Surgery

Volumn 84, Issue 4, 1999, Pages 279-290

  Turvey, Stuart E ^a   Wood, Kathryn J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Immunobiology; Rejection; Tolerance; Transplantation

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

ALLOTRANSPLANTATION; ANIMAL; GRAFT REJECTION; HISTOCOMPATIBILITY; HUMAN; IMMUNOLOGY; ORGAN TRANSPLANTATION; REVIEW; T LYMPHOCYTE;

ANIMALS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; T-LYMPHOCYTES; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS;

EID: 0033201894     PISSN: 00208868     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (87)

1. Geest SD, Borgermans L, Gemoets H, Abraham I, Vlaminck H, Evers G et al. Incidence, determinants, and consequences of subclinical noncompliance with immunosuppressive therapy in renal transplant recipients. Transplantation 1995; 59: 340-7
2. Penn I. Cancers complicating organ transplantation. N Engl J Med 1990; 323: 1767-9
3. London NJ, Farmery SM, Will EJ, Davison AM, Lodge PA. Risk of neoplasia in renal transplant patients. Lancet 1995; 346: 403-6
4. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338: 1741-51
5. Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397: 530-4
6. Azuma H, Tilney NL. Chronic graft rejection. Curr Opin Immunol 1994; 6: 770-6
7. Evans RW, Orians CE, Ascher NL. The potential supply of organ donors: an assessment of the efficiency of organ procurement efforts in the United States. JAMA 1992; 267: 239-46
8. Platt JL. New directions for organ transplantation. Nature 1998; 392 (Suppl): 11-7
9. Billingham RE, Brent L, Medawar PB. 'Actively acquired tolerance' of foreign cells. Nature 1953; 172: 603-6
10. Mazariegos GV, Ramos H, Shapiro R, Zeevi A, Fung JJ, Starzl TE. Weaning of immunosuppression in long-term recipients of living-related renal transplants: a preliminary study. Transplant Proc 1995; 27: 207
11. Mazariegos GV, Reyes J, Marino IR, Demetris AJ, Flynn B, Irish W et al. Weaning of immunosuppression in liver transplant recipients. Transplantation 1997; 63: 243-249.
12. Hall BM, Dorsch S, Roser B. The cellular basis of allograft rejection in vivo 1: the cellular requirements for first-set rejection of heart grafts. J Exp Med 1978; 148: 878-89
13. Bolton EM, Gracie JA, Briggs JD, Kampinga J, Bradley JA. Cellular requirements for renal allograft rejection in the athymic nude rat. J Exp Med 1989; 169: 1931-46
14. Waldmann TA, O'Shea J. The use of antibodies against the IL-2 receptor in transplantation. Curr Opin Immunol 1998; 10: 507-12
15. Krensky AM, Weiss A, Crabtree G, Davis MM, Parham P. T-lymphocyte-antigen interactions in transplant rejection. N Engl J Med 1990; 322: 510-7
16. Zinkernagel RM, Doherty PC. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 1974; 248: 701-2
17. Zinkernagel RM, Doherty PC. Immunological surveillance against altered self components by sensitised T lymphocytes in lymphocytic choriomeningitis. Nature 1974; 251: 547-8
18. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 1987; 329: 512-8
19. Garboczi DN, Ghosh P, Utz U, Fan QR, Biddison WE, Wiley DC. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 1996; 384: 134-41
20. Garcia KC, Degano M, Stanfield RL, Brunmark A, Jackson MR, Peterson PA et al. An ab T cell receptor structure at 2.5 Å and its orientation in the TCR-MHC complex. Science 1996; 274: 209-19
21. Sayegh MH, Watschinger B, Carpenter CB. Mechanisms of T cell recognition of alloantigen: the role of peptides. Transplantation 1994; 57: 1295-302
22. Lechler RI, Lombardi G, Batchelor JR, Reinsmoen N, Bach FH. The molecular basis of alloreactivity. Immunol Today 1990; 11: 83-8
23. Shoskes DA, Wood KJ. Indirect presentation of MHC antigens in transplantation. Immunol Today 1994; 15: 32-8
24. Gould DS, Auchincloss H. Direct and indirect recognition: the role of MHC antigens in graft rejection. Immunol Today 1999; 20: 77-82
25. Braun MY, McCormack A, Webb G, Bachelor JR. Mediation of acute but not chronic rejection of MHC-incompatible rat kidney grafts by alloreactive CD4 T cells activated by the direct pathway of sensitization. Transplantation 1993; 55: 177-82
26. Benichou G, Valujskikh A, Heeger PS. Contributions of direct and indirect T cell alloreactivity during allograft rejection in mice. J Immunol 1999; 162: 352-8
27. Lafferty KJ, Prowse SJ, Simeonovic CJ. Immunobiology of tissue rejection: a return to the passenger leukocyte concept. Annu Rev Immunol 1983; 1: 143-73
28. Vella JP, Spadafora-Ferreira M, Murphy B, Alexander SI, Harmon W, Carpenter CB et al. Indirect allorecognition of major histocompatibility complex allopeptides in human renal transplant recipients with chronic graft dysfunction. Transplantation 1997; 64: 795-800
29. Ciubotariu R, Liu Z, Colovai AI, Ho E, Itescu S, Ravalli S et al. Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts. J Clin Invest 1998; 101: 398-105
30. Auchincloss H, Lee R, Shea S, Markowitz JS, Grusby MJ, Glimcher LH. The role of 'indirect' recognition in initiating rejection of skin grafts from major histocompatibility complex class II-deficient mice. Proc Natl Acad Sci USA 1993; 90: 3373-7
31. Valujskikh A, Matesic D, Gilliam A, Anthony D, Haqqi TM, Heeger PS. T cells reactive to a single immunodominant self-restricted allopeptide induce skin graft rejection in mice. J Clin Invest 1998; 101: 1398-407
32. Wise M, Zelenika D, Bemelman F, Latinne D, Bazin H, Cobbold S et al. CD4 T cells can reject major histocompatibility complex class I-incompatible skin grafts. Eur J Immunol 1999; 29: 156-67
33. Janeway CA, Bottomly K. Signals and signs for lymphocyte responses. Cell 1994; 76: 275-85
34. Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 1993; 11: 191-212
35. Lee K, Chuang E, Griffin M, Khattri R, Hong DK, Zhang W et al. Molecular basis of T cell inactivation by CTLA-4. Science 1999; 282: 2263-6
36. Walunas TL, Bakker CY, Bluestone JA. CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 1996; 183: 2541-50
37. Larsen CP, Pearson TC. The CD40 pathway in allograft rejection, acceptance, and tolerance. Curr Opin Immunol 1997; 9: 641-7
38. Larsen CP, Steinman RM, Witmr-Pack M, Hankins DF, Morris PJ, Austyn JM. Migration and maturation of Langerhans cells in skin transplants and explants. J Exp Med 1990; 172: 1483-93
39. Larsen CP, Ritchie SC, Pearson TC, Linsley PS, Lowry RP. Functional expression of the costimulatory molecule, B7/BB1, on murine dendritic cell populations. J Exp Med 1992; 176: 1215-20
40. Luster AD. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338: 436-45
41. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76: 301-14
42. Fuggle SV, Koo DDH. Cell adhesion molecules in clinical renal transplantation. Transplantation 1998; 65: 763-9
43. Kablitz D. Apoptosis, graft rejection, and transplantation tolerance. Transplantation 1998; 65: 869-75
44. Strehlau J, Pavlakis M, Lipman M, Shapiro M, Vasconcellos L, Harmon W et al. Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation. Proc Natl Acad Sci USA 1997; 94: 695-700
45. Kissmeyer-Nielsen F, Olsen S, Petersen VP, Fjeldborg O. Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet 1966; 2: 662-5
46. Scornik JC, Salomon DR, Lim PB, Howard RJ, Pfaff WW. Posttransplant antidonor antibodies and graft rejection: evaluation by two-color flow cytometry. Transplantation 1989; 47: 287-90
47. Suciu-Foca N, Reed E, D'Agati VD, Ho E, Cohen DJ, Benvenisty AI et al. Soluble HLA antigens, anti-HLA antibodies, and antiidiotypic antibodies in the circulation of renal transplant recipients. Transplantation 1991; 51: 593-601
48. First MR. An update on new immunosuppressive drugs undergoing preclinical and clinical trials: potential applications in organ transplantation. Am J Kidney Dis 1997; 29: 303-17
49. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321-5
50. Kappler J, Rohm N, Marrack P. T cell tolerance by clonal elimination in the thymus. Cell 1987; 49: 273-80
51. + thymocytes. Nature 1988; 333: 742-6
52. Posselt AM, Barker CF, Tomaszewski JE, Markmann JF, Choti MA, Naji A. Induction of donor-specific unresponsiveness by intrathymic islet transplantation. Science 1990; 249: 1293-5
53. Turvey SE, Fry JW, Wood KJ. New insights into the mechanisms of acquired intrathymic tolerance. Curr Opin Organ Transplant 1999; 4: 50-7
54. Posselt AM, Barker CF, Friedman AL, Naji A. Prevention of autoimmune diabetes in the BB rat by intrathymic islet transplantation at birth. Science 1992; 256: 1321-4
55. Khoury SJ, Sayegh MH, Hancock WW, Gallon L, Carpenter CB, Weiner HL. Acquired tolerance to experimental autoimmune encephalomyelitis by intrathymic injection of myelin basic protein or its encephalitogenic peptide. J Exp Med 1993; 178: 559-66
56. Tyden G, Reinholt FP, Sundkvist G, Bolinder J. Recurrence of autoimmune diabetes mellitus in recipients of cadaveric pancreatic grafts. N Engl J Med 1996; 335: 860-3
57. Tomita Y, Khan A, Sykes M. Role of intrathymic clonal deletion and peripheral anergy in transplantation tolerance induced by bone marrow transplantation in mice conditioned with a nonmyeloablative regimen. J Immunol 1994; 153: 1087-98
58. Manilay JO, Pearson DA, Sergio JJ, Swenson KG, Sykes M. Intrathymic deletion of alloreactive T cells in mixed bone marrow chimeras prepared with a nonmyeloablative conditioning regimen. Transplantation 1998; 66: 96-102
59. Schwartz RH. T cell clonal anergy. Curr Opin Immunol 1997; 9: 351-7
60. Dossetor JB, MacKinnon KJ, Gault MH, MacLean LD. Cadaver kidney transplants. Transplantation 1967; 5: 844-53
61. Morris PJ, Ting A, Stocker J. Leukocyte antigens in renal transplantation 1: the paradox of blood transfusions in renal transplantation. Med J Aust 1968; 2: 1088-90
62. Opelz G, Vanrenterghem Y, Kirste G, Gray DWR, Horsburgh T, Lachance JG et al. Prospective evaluation of pretransplant blood transfusions in cadaver kidney recipients. Transplantation 1997; 63: 964-7
63. Lagaaij EL, Hennemann IPH, Ruigrok M, Haan MWD, Persijn GG, Termijtelen A et al. Effect of one-HLA-DR-antigen-matched and completely HLA-DR-mismatched blood transfusions on survival of heart and kidney allografts. N Engl J Med 1989; 321: 701-5
64. Sayegh MH, Turka LA. The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 1998; 338: 1813-21
65. Turka LA, Linsley PS, Lin H, Brady W, Leiden JM, Wei R, et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 1992; 89: 11102-5
66. Lenschow DJ, Zeng Y, Thistlewaite JR, Montag A, Brady W, Gibson MG et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 1992; 257: 789-92
67. Sayegh MH. Finally, CTLA4Ig graduates to the clinic. J Clin Invest 1999; 103: 1223-5
68. Larsen CP, Alexander DZ, Hollenbaugh D, Elwood ET, Ritchie SC, Aruffo A et al. CD40-gp39 interactions play a critical role during allograft rejection: suppression of allograft rejection by blockade of the CD40-gp39 pathway. Transplantation 1996; 61: 4-9
69. Hancock WW, Buelow R, Sayegh MH, Turka LA. Antibody-induced transplantation arteriosclerosis is prevented by graft expression of anti-oxidant and anti-apoptotic genes. Nat Med 1998; 4: 1392-6
70. Larsen CP, Elwood ET, Alexander DZ, Ritchie SC, Hendrix R, Tucker-Burden C et al. Long-term acceptance of skin and cardiac allographs after blocking CD40 and CD28 pathways. Nature 1996; 381: 434-8
71. Kirk AD, Harlan DM, Armstrong NH, Davis TD, Dong Y, Gray GS et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 1997; 94: 8789-94
72. Isobe M, Yagita H, Okumura K, Ihara A. Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science 1992; 255: 1125-7
73. Calne RY, Sells RA, Pena JR, Davis DR, Millard PR, Herbertson BM et al. Induction of immunological tolerance by porcine liver allografts. Nature 1969; 223: 472-6
74. Hamano K, Rawsthorne M, Bushell AR, Morris PJ, Wood KJ. Evidence that the continued presence of the organ graft and not peripheral donor microchimerism is essential for the maintenance of tolerance to alloantigen in vivo in anti-CD4 treated recipients. Transplantation 1996; 62: 856-60
75. Jones ND, Fluck NC, Mellor AL, Morris PJ, Wood KJ. The induction of transplantation tolerance by intrathymic (i.t.) delivery of alloantigen: a critical relationship between i.t. deletion, thymic export of new T cells and the timing of transplantation. Int Immunol 1998; 10: 1637-46
76. Markmann J, Lo D, Naji A, Palmiter RD, Brinster RL, Heber-Katz E. Antigen presenting function of class II MHC expressing pancreatic beta cells. Nature 1988; 336: 476-9
77. Marelli-Berg FM, Weetman A, Frasca L, Deacock SJ, Imami N, Lombardi G et al. Antigen presentation by epithelial cells induces anergic immunoregulatory CD45RO+ T cells and deletion of CD45RA+ T cells. J Immunol 1997; 159: 5853-61
78. Starzl TE, Demetris AJ, Murase N, Ildstad S, Riccordi C, Trucco M. Cell migration, chimerism and graft acceptance. Lancet 1992; 339: 1579-82
79. Wood K, Sachs DH. Chimerism and transplantation tolerance: cause and effect. Immunol Today 1996; 17: 584-7
80. Starzl TE, Zinkernagel RM. Antigen localization and migration in immunity and tolerance. N Engl J Med 1998; 339: 1905-13
81. Thomson AW, Lu L. Are dendritic cells the key to liver transplantation tolerance? Immunol Today 1999; 20: 27-32
82. Mason D, Powrie F. Control of immune pathology by regulatory T cells. Curr Opin Immunol 1998; 10: 649-55
83. Gunther J, Haas W, von Boehmer H. Suppression of T cell responses through competition for T cell growth factor (interleukin 2). Eur J Immunol 1982; 12: 247-9
84. Lombardi G, Sidhu S, Batchelor R, Lechler R. Anergic T cells as suppressor cells in vitro. Science 1994; 264: 1587-9
85. Taams LS, van Rensen AJML, Poelen MCM, van Els CAM, Besseling AC, Wagenaar JPA et al. Anergic T cells actively suppress T cell responses via the antigen-presenting cell. Eur J Immunol 1998; 28: 2902-12
86. Islet Registry Web Page. http: //www.med.uni-giessen.de/itr/
87. Mackall CL, Fleisher TA, Brown MR, Andrich MP, Chen CC, Feuerstein IM et al. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995; 332: 143-9